跳至主要内容
临床试验/EUCTR2020-002314-40-AT
EUCTR2020-002314-40-AT进行中(未招募)1 期

A Pilot study platform to investigate the pharmacodynamics on QT-prolongation and pharmacokinetics after multiple dose administration of potential combination treatments for COVID-19 in healthy volunteers

Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie0 个研究点目标入组 16 人开始时间: 2020年7月15日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age: between =18 and = 59 years old, has a body weight of at least 50 kg and has a body mass index (BMI) of 18 to 32 kg/m², inclusive
  • Ability to comprehend the full nature and purpose of the study, including possible risks.
  • Physical examination and laboratory analysis: no presence of clinically relevant abnormal findings or values which the investigator considers may interfere with the objectives of the present study.
  • The female subject agrees to sexual abstinence, or is surgically sterile, postmenopausal (defined as at least 2 years at Screening without menses), or using a medically acceptable double barrier method (e.g. spermicide and diaphragm, or spermicide and condom) to prevent pregnancy and agrees to continue using this method from Screening until 3 weeks after the follow-up visit at the end of the study; and is not lactating or pregnant as documented by negative pregnancy tests at Screening and day 1
  • The male subject agrees to sexual abstinence, is surgically sterile, or is using a medically acceptable method to prevent pregnancy and agrees to continue using this method from Screening until 3 weeks after the follow-up visit at the end of the study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 16
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Age:<18 years old
  • Unwillingness to sign the informed consent
  • The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes)
  • The subject has a history of pancreatitis
  • The subject has a positive result for hepatitis C antibodies, hepatitis B surface antigen at Screening or is known to be positive for human immunodeficiency virus (HIV) (Virology results not older than 6 months prior to screening are acceptable)
  • The subject has a known or suspected allergy to any of the components of the trial products including ribavirin or lopinavir/ritonavir or a history of multiple and/or severe allergies to drugs or foods (as judged by the investigator), or a history of severe anaphylactic reactions- - The subject is a smoker (regular use of tobacco or nicotine containing products) within 1 month prior to screening
  • The subject has had treatment with prescription drugs or complementary and alternative medicines within 14 days prior to Day 1, or over-the-counter medications within 1 week prior to Day 1, with the exception of paracetamol up to 1 g/day
  • The subject has a recent history (within the last 2 years) of drug or alcohol abuse, as defined by the investigator, or a positive drug and/or alcohol screen
  • Inability to comprehend the full nature and purpose of the study

研究者

发起方
Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie

相似试验